Previous 10 | Next 10 |
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conf...
COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presenta...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will in...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock...
Ligand Pharmaceuticals is an intriguing business with a differentiated business model. The company has seen many moving parts, both on the buy and sell side of the business. I like the promise of the business, but execution is not convincing in recent times. While I see appeal...
Berkshire Hathaway to acquire all outstanding Alleghany shares for $848.02 per share in cash, for a total equity value of approximately $11.6 billion. This is one of the five largest acquisitions in Berkshire's history and it ends Buffett's six-year drought of large acquisitions. ...
A new Special Purpose Acquisition Corp. arrangement may open the door to more successful SPAC mergers. The deal, once completed, involves a pharmaceutical company spinning off a division, which will then be acquired by the SPAC. There are several positive aspects for the shareholders of the or...
Ligand Pharmaceuticals (LGND) signs merger agreement with Avista Public Acquisition (AHPAU) a SPAC, providing for the spin-off of OmniAb, Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will b...
Transaction will result in OmniAb becoming an independent publicly traded company Ligand’s shareholders to receive 100% of Ligand’s shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporated (Lig...
Ligand Pharmaceuticals Incorporated (LGND) Q4 2021 Earnings Conference Call February 17, 2022 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Chief Financial Officer Matt Foehr - Chief Operating Officer Confer...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...